Aspirin study
This article was originally published in The Tan Sheet
Executive Summary
Peter Gann, MD, Northwestern University Medical School, et al., concluded that "regular aspirin use, at a dose adequate for preventing myocardial infarction, was not associated with a substantial reduction in the incidence of colorectal cancer during five years of randomized treatment and follow-up." Published in the Aug. 4 Journal of the National Cancer Institute, the study also inferred that low-dose aspirin users are not likely to have an increased incidence of colorectal cancer due to aspirin-induced G-I bleeding. However, Gann et al. recommended that additional epidemiologic studies and prevention trials be undertaken to assess the potential benefits of higher doses of aspirin or a longer duration of use.